BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24005342)

  • 1. Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation.
    Shirahata A; Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kajiki M; Honda G; Sakata Y
    Eur J Pediatr; 2014 Mar; 173(3):303-11. PubMed ID: 24005342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy.
    Asakura H; Takahashi H; Tsuji H; Matsushita T; Ninomiya H; Honda G; Mimuro J; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 Mar; 133(3):364-70. PubMed ID: 24440141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of the safety and efficacy of recombinant human soluble thrombomodulin in patients with obstetrical disseminated intravascular coagulation.
    Kobayashi T; Kajiki M; Nihashi K; Honda G
    Thromb Res; 2017 Nov; 159():109-115. PubMed ID: 29153952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.
    Mimuro J; Takahashi H; Kitajima I; Tsuji H; Eguchi Y; Matsushita T; Kuroda T; Sakata Y
    Thromb Res; 2013 May; 131(5):436-43. PubMed ID: 23566534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing Surveillance of Recombinant Human Soluble Thrombomodulin (Thrombomodulin α) in Pediatric Patients With Disseminated Intravascular Coagulation.
    Shirahata A; Mimuro J; Takahashi H; Tsuji H; Kitajima I; Matsushita T; Eguchi Y; Kitamura N; Honda G; Sakata Y
    Clin Appl Thromb Hemost; 2014 Jul; 20(5):465-72. PubMed ID: 24563247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial.
    Tamura K; Saito H; Asakura H; Okamoto K; Tagawa J; Hayakawa T; Aoki N
    Int J Clin Oncol; 2015 Aug; 20(4):821-8. PubMed ID: 25385713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
    Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.
    Saito H; Maruyama I; Shimazaki S; Yamamoto Y; Aikawa N; Ohno R; Hirayama A; Matsuda T; Asakura H; Nakashima M; Aoki N
    J Thromb Haemost; 2007 Jan; 5(1):31-41. PubMed ID: 17059423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment-A Cohort Study Using a Postmarketing Surveillance Database.
    Yoshinobu S; Honda G; Kawano N; Uchiyama T; Kawasugi K; Madoiwa S; Takezako N; Takayuki I; Wada H
    Clin Appl Thromb Hemost; 2021; 27():10760296211054094. PubMed ID: 34870471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation.
    Eguchi Y; Gando S; Ishikura H; Saitoh D; Mimuro J; Takahashi H; Kitajima I; Tsuji H; Matsushita T; Tsujita R; Nagao O; Sakata Y
    J Intensive Care; 2014; 2(1):30. PubMed ID: 25520842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit Profile of Thrombomodulin Alfa Combined with Antithrombin Concentrate in Patients with Sepsis-Induced Disseminated Intravascular Coagulation.
    Murao A; Kato T; Yamane T; Honda G; Eguchi Y
    Clin Appl Thromb Hemost; 2022; 28():10760296221077096. PubMed ID: 35166576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial.
    Aikawa N; Shimazaki S; Yamamoto Y; Saito H; Maruyama I; Ohno R; Hirayama A; Aoki Y; Aoki N
    Shock; 2011 Apr; 35(4):349-54. PubMed ID: 21068698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
    Hashimoto D; Chikamoto A; Miyanari N; Ohara C; Kuramoto M; Horino K; Ohshima H; Baba H
    J Surg Res; 2015 Aug; 197(2):405-11. PubMed ID: 25972310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
    Mitaka C; Kawagoe I; Satoh D; Hayashida M
    Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
    BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
    J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia.
    Ookura M; Hosono N; Tasaki T; Oiwa K; Fujita K; Ito K; Lee S; Matsuda Y; Morita M; Tai K; Negoro E; Kishi S; Iwasaki H; Ueda T; Yamauchi T
    Medicine (Baltimore); 2018 Nov; 97(44):e12981. PubMed ID: 30383650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors.
    Kashiwagi S; Asano Y; Takahashi K; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 May; 39(5):2259-2264. PubMed ID: 31092417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC.
    Aota T; Wada H; Yamashita Y; Matsumoto T; Ohishi K; Suzuki K; Imai H; Usui M; Isaji S; Katayama N
    Int J Hematol; 2016 Feb; 103(2):173-9. PubMed ID: 26590919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Recombinant Human Soluble Thrombomodulin for Disseminated Intravascular Coagulation.
    Itoh S; Shirabe K; Kohnoe S; Sadanaga N; Kajiyama K; Yamagata M; Anai H; Harimoto N; Ikegami T; Yoshizumi T; Maehara Y
    Anticancer Res; 2016 May; 36(5):2493-6. PubMed ID: 27127163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.